Dr. Reddy's Laboratories, a prominent player in the global pharmaceutical industry, is headquartered in Hyderabad, India. Founded in 1984, the company has established itself as a leader in the development and manufacturing of a wide range of generic medications, active pharmaceutical ingredients (APIs), and proprietary products. With a strong presence in markets across North America, Europe, and Asia, Dr. Reddy's is committed to providing affordable healthcare solutions. The company’s core offerings include generic formulations, biosimilars, and over-the-counter products, distinguished by their quality and innovation. Dr. Reddy's has achieved significant milestones, including numerous product launches and strategic partnerships, solidifying its market position. Recognised for its commitment to sustainability and patient-centric approach, Dr. Reddy's Laboratories continues to make strides in enhancing global health outcomes.
How does Dr Reddys Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Dr Reddys Laboratories's score of 91 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2025, Dr. Reddy's Laboratories reported global carbon emissions of approximately 142,772,000 kg CO2e for Scope 1, 94,690,000 kg CO2e for Scope 2 (market-based), and 845,849,000 kg CO2e for Scope 3. This reflects a commitment to reducing greenhouse gas emissions across all scopes, with specific targets set for the future. The company aims to achieve a 50.2% reduction in Scope 1 and 2 emissions per million USD revenue by FY2031, using FY2021 as the base year. This translates to an approximate 25% absolute reduction in these emissions. Additionally, Dr. Reddy's has committed to a 12.3% reduction in absolute Scope 3 emissions within the same timeframe. Dr. Reddy's Laboratories has also pledged to transition to 100% renewable power by 2030, further enhancing its sustainability efforts. The targets are aligned with the Science Based Targets initiative (SBTi) and are classified as consistent with keeping global warming well below 2°C. Overall, Dr. Reddy's Laboratories is actively working towards significant emissions reductions while maintaining transparency in its climate commitments.
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 177,841,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 254,563,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Dr Reddys Laboratories has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Dr Reddys Laboratories's sustainability data and climate commitments